Gedeon Richter has become the latest firm to throw its hat into the ring for a denosumab biosimilar, after revealing that the European Medicines Agency has accepted for review the firm’s two marketing authorization applications for proposed rivals to Prolia and Xgeva.
Richter said its two MAAs “include all indications covered by the reference biologics,” such as treating osteoporosis in postmenopausal women,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?